Exelixis Appoints New Executive VP for R&D Amid Leadership Transition

Exelixis, a biotechnology company, has appointed Dana T. Aftab as Executive Vice President of Research and Development, replacing Amy C. Peterson. This leadership change may impact the company's strategic direction and market positioning. Exelixis focuses on developing targeted therapies for cancer treatment. The company's stock has a Buy rating with a $43.00 price target and a moderate valuation.

Exelixis, Inc. (Nasdaq: EXEL), a leading biotechnology company focused on developing targeted therapies for cancer treatment, has appointed Dr. Dana T. Aftab as its new Executive Vice President of Research and Development. This appointment replaces Amy C. Peterson, who previously held the position. The leadership change comes as Exelixis continues to expand its portfolio of cancer treatments.

Dr. Aftab brings over 25 years of experience at Exelixis, where he has played a pivotal role in driving scientific innovation and development. He has been instrumental in the discovery, development, and commercialization of several key products, including CABOMETYX® (cabozantinib), a leading tyrosine kinase inhibitor for advanced renal cell carcinoma and neuroendocrine tumors. Dr. Aftab's extensive background in drug discovery and development, coupled with his expertise in translational research, positions him well to lead Exelixis' product development organization [1].

The appointment of Dr. Aftab coincides with Exelixis' ongoing efforts to maximize the potential of its portfolio, which includes zanzalintinib, a third-generation oral tyrosine kinase inhibitor currently undergoing multiple pivotal trials. The company's early-stage pipeline also features promising small molecules and biotherapeutics, all of which will be overseen by Dr. Aftab in his new role.

Exelixis' stock has been performing well, with a Buy rating and a $43.00 price target as of July 2025. The company's moderate valuation reflects its strategic focus on innovation and the potential of its pipeline to deliver transformational treatments for cancer patients.

Forward-looking statements in this press release, including those related to Exelixis' senior officer transitions, involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties [2].

References:
[1] https://www.morningstar.com/news/business-wire/20250829389096/exelixis-announces-appointment-of-dana-t-aftab-phd-as-executive-vice-president-research-and-development
[2] https://www.businesswire.com/news/home/20250219147539/en/Exelixis-Announces-U.S.-FDA-Approval-of-CABOMETYX-cabozantinib-for-Patients-with-Previously-Treated-Advanced-Neuroendocrine-Tumors